INO · Inovio Pharmaceuticals, Inc.
$1.09
+0.19 (+21.10%)
At close · Aug 14
View the 10-K filed Mar 12, 2026
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$112.70M
Shares
103.40M
Stock transactions by members of the U.S. Congress, disclosed under the STOCK Act. Lawmakers must report trades within 45 days, so the filing date can lag the trade itself.
| Date | Member | Position | Type | Owner | Amount | Filed | Lag |
|---|---|---|---|---|---|---|---|
| 2020-09-08 | Christopher L. Jacobs | Representative | Sell | — | $1K - $15K | 2020-11-06 | 59d late |
Showing 1–1 of 1 trades
Key facts
CIK
1055726
CUSIP
45773H409
13F (30d)
103 filings
101 filers
Visit website
Investor relations